Mizuho Maintains Outperform on LifeMD, Lowers Price Target to $6
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Mizuho analyst Steven Valiquette maintains LifeMD (NASDAQ:LFMD) with a Outperform and lowers the price target from $7 to $6.
Mizuho analyst Steven Valiquette maintains LifeMD (NASDAQ:LFMD) with a Outperform and lowers the price target from $7 to $6.
